Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the sale, the senior vice president now owns 38,116 shares of the company’s stock, valued at approximately $1,029,132. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Boston Scientific Corporation (BSX) opened at $27.63 on Friday. Boston Scientific Corporation has a 1-year low of $23.29 and a 1-year high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $38,394.56 and a P/E ratio of 45.30.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.34. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The firm had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same period last year, the company earned $0.30 EPS. Boston Scientific’s quarterly revenue was up 9.9% compared to the same quarter last year. research analysts forecast that Boston Scientific Corporation will post 1.26 earnings per share for the current year.
BSX has been the topic of several recent research reports. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. TheStreet cut Boston Scientific from a “b” rating to a “c+” rating in a research report on Thursday, December 7th. BMO Capital Markets reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday, December 12th. Canaccord Genuity decreased their price objective on Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $31.00.
Hedge funds have recently modified their holdings of the stock. Sit Investment Associates Inc. lifted its stake in shares of Boston Scientific by 37.8% during the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after acquiring an additional 38,855 shares during the last quarter. Greenwood Capital Associates LLC raised its position in Boston Scientific by 71.7% during the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock valued at $2,671,000 after purchasing an additional 38,249 shares in the last quarter. Knights of Columbus Asset Advisors LLC raised its position in Boston Scientific by 94.9% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock valued at $1,126,000 after purchasing an additional 18,800 shares in the last quarter. LS Investment Advisors LLC raised its position in Boston Scientific by 5.8% during the 3rd quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock valued at $1,185,000 after purchasing an additional 2,209 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. raised its position in Boston Scientific by 1.4% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock valued at $34,934,000 after purchasing an additional 16,992 shares in the last quarter. 90.59% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/02/david-a-pierce-sells-5152-shares-of-boston-scientific-corporation-bsx-stock.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.